Amivantamab: A narrative drug review

Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an alter...

Full description

Bibliographic Details
Published in:Cancer Research, Statistics, and Treatment
Main Authors: Anupa John, Vanita Noronha, Ajaykumar Singh, Nandini Menon, Kumar Prabhash
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Subjects:
exon 20ins
exon 20
nsclc
met
bispecific antibody
humanized
jnj-61186372
Online Access:http://www.crstonline.com/article.asp?issn=2590-3233;year=2023;volume=6;issue=2;spage=261;epage=271;aulast=John

Internet

http://www.crstonline.com/article.asp?issn=2590-3233;year=2023;volume=6;issue=2;spage=261;epage=271;aulast=John

Similar Items